Market Research Logo

PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services

PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Summary


Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.

According to this latest report, PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services, the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a “boom or bust” proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity.

Scope

  • Follow the Money: The Outlook for Outsourced Spending on Early Development Services exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.
Reasons to buy

This report provides important insight that you won’t find in any other source. This report is required reading for -
  • CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking
  • Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence
  • Private equity: investment targeting, portfolio company performance benchmarking


Executive Summary
Context and Objectives
Clinical Trial Activity of Emerging Bio/Pharma Companies
Clinical Development Costs and Spending by Emerging Bio/Pharma Companies
External Financing for Emerging Bio/Pharma Companies
Outlook and What it Means
Appendix A
Appendix B
1.1 List of Tables
Table 1 2016 Performance of Drug Development Service Providers
Table 2 Profile of Emerging Bio/Pharma IPOs 2014-
1.2 List of Figures
Figure 1 Breakdown of Phase I and Phase II Trials by Primary Sponsor, H1 2012-H1
Figure 2 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-IPO
Figure 3 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-SPO
Figure 4 Estimated Cost of Getting Candidates Through Clinical Trial Phases
Figure 5 Ownership of Emerging Bio/Pharma Companies Sponsoring Clinical Trials H1
Figure 6 Equity Funding to Emerging Bio/Pharma 2010-
Figure 7 Venture Capital Investment in Bio/Pharma Companies
Figure 8 VC Funding to Emerging Bio/Pharma 2010-
Figure 9 NASDAQ Biotech Index January 13-December
Figure 10 R&D Spend and Cash Runway for US Emerging Bio/Pharma Companies
Figure 11 Revenue as a Funding Source for US Emerging BioPharma
Figure 12 Proportion of Companies with > 2 Years Cash or Increasing Cash Reserves

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report